Skip to main content
SpringerLink
Log in

Telotristat for CSD treatment: "minimal" budget impact

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by Lexicon Pharmaceuticals.

Reference

  • Joish VN, et al. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clinical Therapeutics : 23 Nov 2017. Available from: URL: http://doi.org/10.1016/j.clinthera.2017.10.019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Telotristat for CSD treatment: "minimal" budget impact. PharmacoEcon Outcomes News 793, 31 (2017). https://doi.org/10.1007/s40274-017-4591-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4591-6

Search

Navigation